|
1
|
Zheng RS, Chen R, Han BF, Wang SM, Li L,
Sun KX, Zeng HM, Wei WW and He J: Cancer incidence and mortality in
China, 2022. Zhonghua Zhong Liu Za Zhi. 46:221–231. 2024.(In
Chinese). PubMed/NCBI
|
|
2
|
Thawani R, Fakhoury K and Becker KD: Cause
of mortality in patients with lung cancer and brain metastasis. J
Clin Oncol. 38:e21743. 2020. View Article : Google Scholar
|
|
3
|
Ernani V and Stinchcombe TE: Management of
brain metastases in non-small-cell lung cancer. J Oncol Pract.
15:563–570. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Howlader N, Forjaz G, Mooradian MJ, Meza
R, Kong CY, Cronin KA, Mariotto AB, Lowy DR and Feuer EJ: The
effect of advances in lung-cancer treatment on population
mortality. N Engl J Med. 383:640–649. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duma N, Santana-Davila R and Molina JR:
Non-small cell lung cancer: Epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suda K, Mitsudomi T, Shintani Y, Okami J,
Ito H, Ohtsuka T, Toyooka S, Mori T, Watanabe SI, Asamura H, et al:
Clinical impacts of EGFR mutation status: Analysis of 5780
surgically resected lung cancer cases. Ann Thorac Surg.
111:269–276. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR,
Threapleton D, Yang ZY, Mao C and Tang JL: The prevalence of EGFR
mutation in patients with non-small cell lung cancer: A systematic
review and meta-analysis. Oncotarget. 7:78985–78993. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnson M, Garassino MC, Mok T and
Mitsudomi T: Treatment strategies and outcomes for patients with
EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine
kinase inhibitors: Focus on novel therapies. Lung Cancer.
170:41–51. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cooper AJ, Sequist LV and Lin JJ:
Third-generation EGFR and ALK inhibitors: Mechanisms of resistance
and management. Nat Rev Clin Oncol. 19:499–514. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thomas NJ, Myall NJ, Sun F, Patil T,
Mushtaq R, Yu C, Sinha S, Pollom EL, Nagpal S, Camidge DR, et al:
Brain metastases in EGFR- and ALK-positive NSCLC: Outcomes of
central nervous system-penetrant tyrosine kinase inhibitors alone
versus in combination with radiation. J Thorac Oncol. 17:116–129.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Porta R, Sánchez-Torres JM, Paz-Ares L,
Massutí B, Reguart N, Mayo C, Lianes P, Queralt C, Guillem V,
Salinas P, et al: Brain metastases from lung cancer responding to
erlotinib: The importance of EGFR mutation. Eur Respir J.
37:624–631. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hsu F, De Caluwe A, Anderson D, Nichol A,
Toriumi T and Ho C: EGFR mutation status on brain metastases from
non-small cell lung cancer. Lung Cancer. 96:101–107. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liao L, Ji X, Ge M, Zhan Q, Huang R, Liang
X and Zhou X: Characterization of genetic alterations in brain
metastases from non-small cell lung cancer. FEBS Open Bio.
8:1544–1552. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Z, Yuan F, Chen R, Li Y, Ma J, Yan
X, Wang L, Zhang F, Tao H, Guo D, et al: Dynamics of serum tumor
markers can serve as a prognostic biomarker for chinese advanced
non-small cell lung cancer patients treated with immune checkpoint
inhibitors. Front Immunol. 11:11732020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xie X, Qiu G, Chen Z, Liu T, Yang Y, You
Z, Zeng C, Lin X, Xie Z, Qin Y, et al: Characteristics and
prognosis of EGFR mutations in small cell lung cancer patients in
the NGS era. Clin Transl Oncol. 26:434–445. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schoenfeld DA and Richter JR: Nomograms
for calculating the number of patients needed for a clinical trial
with survival as an endpoint. Biometrics. 38:163–170. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Page S, Milner-Watts C, Perna M, Janzic U,
Vidal N, Kaudeer N, Ahmed M, McDonald F, Locke I, Minchom A, et al:
Systemic treatment of brain metastases in non-small cell lung
cancer. Eur J Cancer. 132:187–198. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen BT, Jin T, Ye N, Mambetsariev I,
Daniel E, Wang T, Wong CW, Rockne RC, Colen R, Holodny AI, et al:
Radiomic prediction of mutation status based on MR imaging of lung
cancer brain metastases. Magn Reson Imaging. 69:49–56. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen S, Hua X, Jia J, Wu Y, Wei S, Xu L,
Han S, Zhang H and Zhu X: Risk factors for brain metastases in
patients with non-small cell lung cancer: A meta-analysis of 43
studies. Ann Palliat Med. 10:3657–3672. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oprita A, Baloi SC, Staicu GA, Alexandru
O, Tache DE, Danoiu S, Micu ES and Sevastre AS: Updated insights on
EGFR signaling pathways in glioma. Int J Mol Sci. 22:5872021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Du Z, Brown BP, Kim S, Ferguson D, Pavlick
DC, Jayakumaran G, Benayed R, Gallant JN, Zhang YK, Yan Y, et al:
Structure-function analysis of oncogenic EGFR kinase domain
duplication reveals insights into activation and a potential
approach for therapeutic targeting. Nat Commun. 12:13822021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Romano R and Bucci C: Role of EGFR in the
nervous system. Cells. 9:18872020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Uribe ML, Marrocco I and Yarden Y: EGFR in
cancer: Signaling mechanisms, drugs, and acquired resistance.
Cancers (Basel). 13:27482021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng WL, Feng PH, Lee KY, Chen KY, Sun
WL, VanHiep N, Luo CS and Wu SM: The role of EREG/EGFR pathway in
tumor progression. Int J Mol Sci. 22:128282021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sigismund S, Avanzato D and Lanzetti L:
Emerging functions of the EGFR in cancer. Mol Oncol. 12:3–20. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Piper-Vallillo AJ, Sequist LV and
Piotrowska Z: Emerging treatment paradigms for EGFR-mutant lung
cancers progressing on osimertinib: A Review. J Clin Oncol.
38:2926–2936. 2020. View Article : Google Scholar
|
|
27
|
Hayashi H, Nadal E, Gray JE, Ardizzoni A,
Caria N, Puri T and Grohe C: Overall treatment strategy for
patients with metastatic NSCLC with activating EGFR mutations. Clin
Lung Cancer. 23:e69–e82. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Singh R, Lehrer EJ, Ko S, Peterson J, Lou
Y, Porter AB, Kotecha R, Brown PD, Zaorsky NG and Trifiletti DM:
Brain metastases from non-small cell lung cancer with EGFR or ALK
mutations: A systematic review and meta-analysis of
multidisciplinary approaches. Radiother Oncol. 144:165–179. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rangachari D, Yamaguchi N, VanderLaan PA,
Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE,
Huberman MS and Costa DB: Brain metastases in patients with
EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung
Cancer. 88:108–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Girard N: New strategies and novel
combinations in EGFR TKI-resistant non-small cell lung cancer. Curr
Treat Options Oncol. 23:1626–1644. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma J, Pang X, Zhang S, Huang L, Sun L and
Han C: First-line treatment of EGFR-mutated non-small cell lung
cancer with brain metastases: A systematic review and
meta-analysis. Sci Rep. 14:229012024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pecci F, Cantini L, Metro G, Ricciuti B,
Lamberti G, Farooqi AA and Berardi R: Non-small-cell lung cancer:
How to manage EGFR-mutated disease. Drugs Context. 11:2022–4-1.
2022. View Article : Google Scholar
|
|
33
|
Kwon BS, Cho YH, Yoon SK, Lee DH, Kim SW,
Kwon DH, Lee JC and Choi CM: Impact of clinicopathologic features
on leptomeningeal metastasis from lung adenocarcinoma and treatment
efficacy with epidermal growth factor receptor tyrosine kinase
inhibitor. Thorac Cancer. 11:436–442. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y,
Liu C, Zhu S, Zhang X, Li Y, et al: Furmonertinib (AST2818) versus
gefitinib as first-line therapy for Chinese patients with locally
advanced or metastatic EGFR mutation-positive non-small-cell lung
cancer (FURLONG): A multicentre, double-blind, randomised phase 3
study. Lancet Respir Med. 10:1019–1028. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu S, Dong X, Jian H, Chen J, Chen G, Sun
Y, Ji Y, Wang Z, Shi J, Lu J, et al: AENEAS: A randomized phase III
trial of aumolertinib versus gefitinib as first-line therapy for
locally advanced or metastatic non-small-cell lung cancer with EGFR
Exon 19 deletion or L858R mutations. J Clin Oncol. 40:3162–3171.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ohe Y, Ramalingam S, Reungwetwattana T,
Chewaskulyong B, Dechaphunkul A, Lee KH, Imamura F, Nogami N, Cheng
Y and Cho BC: Osimertinib vs standard of care EGFR-TKI as
first-line treatment in patients with EGFRm advanced NSCLC: FLAURA.
Ann Oncol. 28:x1252017. View Article : Google Scholar
|
|
37
|
Shi Y, Au JSK, Thongprasert S, Srinivasan
S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A
prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lim C, Tsao MS, Le LW, Shepherd FA, Feld
R, Burkes RL, Liu G, Kamel-Reid S, Hwang D, Tanguay J, et al:
Biomarker testing and time to treatment decision in patients with
advanced nonsmall-cell lung cancer. Ann Oncol. 26:1415–1421. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang Y, Ma Y, Li Y, Shen X, Yu Y, Pan Y,
Zhang Y, Yu S, Zheng D, Zhao Y, et al: Are exon 19 deletions and
L858R different in early stage lung adenocarcinoma? J Cancer Res
Clin Oncol. 144:165–171. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Peng X, Long X, Liu L, Zeng L, Yang H,
Jiang W, Liao D, Li K, Wang J and Lizaso A: Clinical impact of
uncommon epidermal growth factor receptor exon 19
insertion-deletion variants on epidermal growth factor
receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung
cancer. Eur J Cancer. 141:199–208. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu CW, Lei L, Wang WX, Lin L, Zhu YC, Wang
H, Miao LY, Wang LP, Zhuang W, Fang MY, et al: Molecular
characteristics and clinical outcomes of EGFR exon 19 C-Helix
deletion in non-small cell lung cancer and response to EGFR TKIs.
Transl Oncol. 13:1007912020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vyse S and Huang PH: Targeting EGFR exon
20 insertion mutations in non-small cell lung cancer. Signal
Transduct Target Ther. 4:52019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gu W, Lu Z, Shi S, Ma J, Lu G, Deng W,
Ding R and Bu F: Molecular characteristics of EGFR exon 19 deletion
subtypes in NSCLC patients. J Clin Oncol. 39:8530. 2021. View Article : Google Scholar
|
|
44
|
Meador CB, Sequist LV and Piotrowska Z:
Targeting EGFR exon 20 insertions in non-small cell lung cancer:
Recent advances and clinical updates. Cancer Discov. 11:2145–2157.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Russo A, Franchina T, Ricciardi G,
Battaglia A, Picciotto M and Adamo V: Heterogeneous responses to
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) in patients with uncommon EGFR mutations: New insights and
future perspectives in this complex clinical scenario. Int J Mol
Sci. 20:14312019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schrock AB, Frampton GM, Herndon D,
Greenbowe JR, Wang K, Lipson D, Yelensky R, Chalmers ZR, Chmielecki
J, Elvin JA, et al: Comprehensive genomic profiling identifies
frequent drug-sensitive EGFR exon 19 deletions in NSCLC not
identified by prior molecular testing. Clin Cancer Res.
22:3281–3285. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lu Z, Yi Y, Wang L, Luo Y, Luo D, Xiong L,
Shu Y, Luo H, Li J, Zhu W, et al: Non-small cell lung cancer cells
with uncommon EGFR exon 19delins variants respond poorly to
third-generation EGFR inhibitors. Transl Oncol. 39:1018342024.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hsiao SH, Chou YT, Lin SE, Hsu RC, Chung
CL, Kao YR, Liu HE and Wu CW: Brain metastases in patients with
non-small cell lung cancer: The role of mutated-EGFRs with an exon
19 deletion or L858R point mutation in cancer cell dissemination.
Oncotarget. 8:53405–53418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang H, Wang L, Gao N, Li H, Yang F, Liu
Z, Li H and Li X: Advances in the treatment of brain metastases in
EGFR-mutant non-small cell lung cancer. Lung Cancer.
206:1086412025. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yenerall P, Kittler R and Minna J:
Structure-based classification of EGFR mutations informs inhibitor
selection for lung cancer therapy. Cancer Cell. 39:1455–1457. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ju JS, Huang ACC, Tung PH, Huang CH, Chiu
TH, Wang CC, Ko HW, Chung FT, Hsu PC, Fang YF, et al: Brain
metastasis, EGFR mutation subtype and generation of EGFR-TKI
jointly influence the treatment outcome of patient with EGFR-mutant
NSCLC. Sci Rep. 13:203232023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huang LT, Zhang SL, Han CB and Ma JT:
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in
EGFR-TKI-Treated advanced non-small-cell lung cancer. Lung Cancer.
166:9–16. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang G, Wang B, Wang Z, Li W, Xiu J, Liu Z
and Han M: Radiomics signature of brain metastasis: Prediction of
EGFR mutation status. Eur Radiol. 31:4538–4547. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liu Y, Dai S, Liu Z, He L, Zhu L, Qin Z,
Fan H, Fang F, Xie Y and Peng X: Serum tumor markers and outcomes
in lung cancer patients with brain metastases: A retrospective
longitudinal cohort study. Transl Lung Cancer Res. 13:2282–2295.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wu H, Wang Q, Liu Q, Zhang Q, Huang Q and
Yu Z: The serum tumor markers in combination for clinical diagnosis
of lung cancer. Clin Lab. 66:2020. View Article : Google Scholar
|
|
56
|
Tang J, Ge QM, Huang R, Shu HY, Su T, Wu
JL, Pan YC, Liang RB, Zhang LJ, Shao Y and Yu Y: Clinical
significance of CYFRA21-1, AFP, CA-153, CEA, and CA-199 in the
diagnosis of lung cancer ocular metastasis in hypertension
population. Front Cardiovasc Med. 8:6705942021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li B, Yuan Q, Zou YT, Su T, Lin Q, Zhang
YQ, Shi WQ, Liang RB, Ge QM, Li QY and Shao Y: CA-125, CA-153, and
CYFRA21-1 as clinical indicators in male lung cancer with ocular
metastasis. J Cancer. 11:2730–2736. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cedrés S, Nuñez I, Longo M, Martinez P,
Checa E, Torrejón D and Felip E: Serum tumor markers CEA,
CYFRA21-1, and CA-125 are associated with worse prognosis in
advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer.
12:172–179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhang L, Liu D, Li L, Pu D, Zhou P, Jing
Y, Yu H, Wang Y, Zhu Y, He Y, et al: The important role of
circulating CYFRA21-1 in metastasis diagnosis and prognostic value
compared with carcinoembryonic antigen and neuron-specific enolase
in lung cancer patients. BMC Cancer. 17:962017. View Article : Google Scholar : PubMed/NCBI
|
